PDGFRA and astrocytoma (excluding glioblastoma): To verify if IDH1/2-mutant astrocytomas with CDKN2A, PDGFRA, CDK4, or MDM2 CNA promotes poor prognosis, we used the GLASS and MSK diffuse glioma datasets (total 1,448 cases) [6, 19].